Founded in 2000 by Charles I. Clough Jr., the firm focuses on providing unique investment solutions for clients by leveraging the deep expertise of its investment team. With offices in Boston and Hong Kong, Clough Capital Partners has a track record of investing in rounds ranging from $50 million to $100 million and has had significant exits in 2017. While the fund is involved in less than 2 investment rounds annually, it stands out by making lead investments 54 percentage points more often than other organizations. The fund has a preference for investing in startups in the therapeutics and genetics industries, and notable portfolio companies include ARMO BioSciences, Arcellx, and Elcelyx Therapeutics.